2024-10-26 - Analysis Report
## Gilead Sciences Inc (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc is a biopharmaceutical company focused on developing and commercializing innovative medicines to treat life-threatening diseases.

**1. Performance Comparison:**

* **Cumulative Return:** GILD has a cumulative return of -8.61% compared to the S&P 500 (VOO) at 135.48%. This represents a significant underperformance.
* **Relative Underperformance:** The current relative underperformance of GILD is -144.09%, which is within the historical range of -148.71% to 18.15%. However, it sits at the 7.18% percentile, indicating a consistently poor performance against the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $88.78
* **5-Day Moving Average:** $87.09
* **20-Day Moving Average:** $85.59
* **60-Day Moving Average:** $80.82
* **Last Market Price:** $88.95

The stock is currently trading above its short-term moving averages, suggesting a potential upward trend in the near term.

**3. Technical Indicators:**

* **RSI:** 73.2. The RSI is considered overbought, indicating potential for a short-term correction.
* **PPO:** 0.02. The PPO is slightly positive, suggesting a slight bullish momentum.
* **Delta_Previous_Relative_Divergence:** +2.15 (positive). This indicates a short-term bullish trend as the stock has been outperforming its recent relative divergence.
* **Expected Return:** 0.0%. This suggests that GILD is not expected to outperform the S&P 500 over the long term (2 years or more).

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report (2024-08-08) showed an EPS of 1.29, exceeding analysts' expectations. Revenue also surpassed estimates, coming in at $6.95 billion. The recent earnings report suggests a positive outlook for the company's future performance.

**5. News and Recent Issues:**

* **Recent Earnings Announcement:** The recent earnings report was well received by the market, with GILD's stock price experiencing a slight upward movement after the announcement. 
* **Market Outlook:** According to FINBOLD, Gilead Sciences is expected to continue its current upward trend, driven by positive earnings reports and strong revenue growth.
* **Analyst Opinions:** Most analysts are optimistic about GILD's future, with a consensus "Buy" rating and a target price of $95.

**6. Overall Analysis:**

GILD has significantly underperformed the S&P 500 over the long term. However, recent earnings reports have been positive, exceeding analysts' expectations and suggesting a possible turnaround. The stock is currently trading above its short-term moving averages and exhibits a short-term bullish trend. Despite the recent positive performance, GILD is not expected to outperform the S&P 500 over the long term.

**7. Conclusion:**

While GILD's past performance has been disappointing, the recent positive earnings reports and optimistic market outlook suggest a potential for future growth. Investors looking for long-term growth opportunities might find GILD's current price attractive, but should be aware of the risks associated with its underperformance and the overall uncertainty in the pharmaceutical industry. 
